| Title: |
SARS-CoV-2 antibody dynamics over time and risk factors associated with infection and long COVID-19 symptoms in large working environments |
| Authors: |
Hansen, Cecilie Bo; Dvoncova, Kristina; Pérez-Alós, Laura; Fogh, Kamille; Madsen, Johannes Roth; Garred, Caroline Hartwell; Jarlhelt, Ida; Nielsen, Pernille Brok; Petersen, Steffan Svejgaard; Fjordager, Charlotte Gandsø; Lauritsen, Klara Tølbøll; Hilsted, Linda; Boding, Lasse; Iversen, Kasper Karmark; Hyveled, Liselotte; Garred, Peter |
| Source: |
Hansen , C B , Dvoncova , K , Pérez-Alós , L , Fogh , K , Madsen , J R , Garred , C H , Jarlhelt , I , Nielsen , P B , Petersen , S S , Fjordager , C G , Lauritsen , K T , Hilsted , L , Boding , L , Iversen , K K , Hyveled , L & Garred , P 2023 , ' SARS-CoV-2 antibody dynamics over time and risk factors associated with infection and long COVID-19 symptoms in large working environments ' , Journal of Internal Medicine .... |
| Publication Year: |
2023 |
| Collection: |
University of Copenhagen: Research / Forskning ved Københavns Universitet |
| Subject Terms: |
antibody; infection; long COVID; SARS-CoV-2; transmission; waning; working environment |
| Description: |
Background Factors influencing SARS-CoV-2 antibody dynamics, transmission, waning and long COVID-19 symptomatology are still not fully understood. Methods In the Danish section of the Novo Nordisk Group, we performed a prospective seroepidemiological study during the first and second waves of the COVID-19 pandemic. All employees and their household members (>18 years) were invited to participate in a baseline (June–August 2020), 6-month follow-up (December 2020–January 2021), and 12-month follow-up (August 2021) sampling. In total, 18,614 accepted and provided at least one blood sample and completed a questionnaire regarding socioeconomic background, health status, previous SARS-CoV-2 infection, and persistent symptoms. Total antibody and specific IgM, IgG and IgA levels against recombinant receptor binding domain were tested. Results At baseline, the SARS-CoV-2-antibody seroprevalence was 3.9%. At 6-month follow-up, the seroprevalence was 9.1%, while at 12-month follow-up, the seroprevalence was 94.4% (after the vaccine roll-out). Male sex and younger age (18–40 years) were significant risk factors for seropositivity. From baseline to the 6-month sampling, we observed a substantial waning of IgM, IgG and IgA levels (p < 0.001), regardless of age, sex and initial antibody level. An increased antibody level was found in individuals infected prior to vaccination compared to vaccinated infection naïves (p < 0.0001). Approximately a third of the seropositive individuals reported one or more persistent COVID-19 symptoms, with anosmia and/or ageusia (17.5%) and fatigue (15.3%) being the most prevalent. Conclusion The study provides a comprehensive insight into SARS-CoV-2 antibody seroprevalence following infection and vaccination, waning, persistent COVID-19 symptomatology and risk factors for seropositivity in large working environments. ; Background: Factors influencing SARS-CoV-2 antibody dynamics, transmission, waning and long COVID-19 symptomatology are still not fully understood. Methods: In the Danish ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| DOI: |
10.1111/joim.13637 |
| Availability: |
https://researchprofiles.ku.dk/da/publications/574f4393-e211-41d2-b1e3-983839aac11c; https://doi.org/10.1111/joim.13637; https://curis.ku.dk/ws/files/359856813/Journal_of_Internal_Medicine_2023_Hansen_SARS_CoV_2_antibody_dynamics_over_time_and_risk_factors_associated_with.pdf |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.4B841FFF |
| Database: |
BASE |